fr   en
Clinical Studies



Browse by date
Or search by keyword
Date: 2006-02-16
Phase: III
Anouncement: Launch
Biotech: Imclone (USA)
Pharma: Merck KGaA (Germany)
Product: Erbitux® (cetuximab)
Disease: squamous cell carcinoma of the head and neck
Country: international study
Other: Patient recruitment has completed for this study aimed at evaluating Erbitux® for the first-line treatment of recurrent and/or metastatic forms of this carcinoma.